Minhong Wu, Pengxiu Lin, Lifang Xu, Zhiling Yu, Qingsheng Chen, Hongyong Gu, Cailing Liu
To investigate the potential prognostic role of serum lactate dehydrogenase (LDH) in patients with urothelial carcinoma (UC) using the method of systematic review and meta-analysis. We searched PubMed, Embase, Cochrane Library, and Web of Science for eligible studies up to February 2020. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the relationship. A total of 14 studies including 4,009 patients with UC were incorporated. The results showed that a high pretreatment serum LDH was associated with an inferior overall survival (OS, HR 1.61, 95% CI 1.39-1.87, < 0.001), cancer-specific survival (CSS, HR 1.41, 95% CI 1.05-1.90, = 0.022), and disease-free survival (DFS, HR 1.64, 95% CI 1.04-2.59, = 0.034) in UC. Subgroup analyses identified that a high pretreatment serum LDH was associated with a poor OS (HR 1.97, 95% CI 1.02-3.81, = 0.042) and DFS (HR 1.64, 95% CI 1.04-2.59, = 0.034) in upper tract urothelial carcinoma, a short OS (HR 1.71, 95% CI 1.37-2.15, < 0.001) in urothelial carcinoma of bladder. Our findings indicated that a high level of pretreatment serum LDH was associated with inferior OS, CSS, and DFS in patients with UC. This biomarker can be an important factor incorporated into the prognostic models for UC.
